Reticular

Interpretable AI for drug discovery

Y CombinatorFall 2024ActiveHealthcareDrug Discovery and DeliveryAI-powered Drug DiscoveryGenerative AIBiotechTherapeutics

What they do

Problem

Pharma companies struggle to reliably steer protein AI models for drug discovery, leading to costly trial-and-error experiments and failed validations.

Solution

Reticular provides interpretability technology that identifies controllable features in protein models (e.g., AlphaFold-like) to make them steerable via prompt-like controls for biological functions.

Who it's for

Pharma companies and early-stage biotech teams using protein foundation models to discover and optimize drugs.

Founders

John Yang

Founder

MIT AI + Mathematics '24. Published ML research in NeurIPS and Nature. Prior quant intern at Goldman Sachs. National achievements include USA Brain Bee Champion, USA Biology Olympiad Bronze Medalist, and First Place Euro Challenge Team Captain.